Advance online publication
The latest papers brought to you ahead of print publication by Nature Clinical Practice. Advance online publication papers are listed below.
About advance online publication
Practice Points
Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?
Published online:
28 October 2008
doi:10.1038/ncponc1262 |
Full Text | PDF (161K)
A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer
Published online:
28 October 2008
doi:10.1038/ncponc1261 |
Full Text | PDF (164K)
Is intravenous iron supplementation with erythropoiesis-stimulating agents beneficial in cancer patients with anemia?
Published online:
21 October 2008
doi:10.1038/ncponc1252 |
Full Text | PDF (163K)
Anal cancer: is neoadjuvant cisplatin chemotherapy or chemoradiotherapy friend or foe?
Published online:
14 October 2008
doi:10.1038/ncponc1258 |
Full Text | PDF (166K)
Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma
Published online:
14 October 2008
doi:10.1038/ncponc1259 |
Full Text | PDF (164K)
Determining the survival benefit of adjuvant radiotherapy in patients with node-positive head and neck cancer
Published online:
30 September 2008
doi:10.1038/ncponc1241 |
Full Text | PDF (164K)
Thalidomide plus dexamethasone as primary therapy for newly diagnosed patients with multiple myeloma
Published online:
09 September 2008
doi:10.1038/ncponc1223 |
Full Text | PDF (167K)
Viewpoints
What is the standard chemotherapy for colorectal cancer patients with resectable liver metastases?
For patients with colorectal cancer and liver metastases, hepatic resection is the only potential curable treatment. The role of adjuvant chemotherapy in this setting is still under debate. The authors of this Viewpoint discuss the final results of the EORTC Intergroup randomized phase III study 40983 and whether FOLFOX4 should be the new standard in patients with resectable colorectal cancer and liver metastases.
Published online:
11 November 2008
doi:10.1038/ncponc1274 |
Full Text | PDF (178K)
The role of cytoreductive nephrectomy for renal cell carcinoma in the era of targeted therapy
Cytoreductive nephrectomy has been a standard treatment for patients with metastatic renal cell carcinoma. The introduction of targeted agents has generated interest in using these drugs pre-operatively. The authors discuss the use of molecular targeted therapy and the benefits of cytoreductive nephrectomy.
Published online:
14 October 2008
doi:10.1038/ncponc1256 |
Full Text | PDF (166K)
Reviews
Why does cytotoxic chemotherapy cure only some cancers?
Despite frequent responses to chemotherapy, curative treatment remains elusive for the majority of metastatic solid tumors. By contrast, chemotherapy routinely cures patients with testicular cancers, gestational choriocarcinoma, Hodgkin's disease and high-grade lymphomas. Savage et al. suggest that the chemo-curability of these malignancies results from an intrinsic 'locked-in' state of sensitivity to pro-apoptotic stresses in these particular cell types, and they discuss some of the characteristics shared by the curable cancers that might explain their curability.
Published online:
04 November 2008
doi:10.1038/ncponc1260 |
Full Text | PDF (350K)
Prophylactic and therapeutic anticoagulation for thrombosis—major issues in oncology
Venous thromboembolism (VTE) is a major cause of morbidity and mortality in patients with cancer. Treatment with low-molecular-weight heparin is the recommended first-line approach for treating cancer patients with newly diagnosed VTE. The authors of this Review discuss the optimal duration of anticoagulant therapy, treatment of recurrent VTE, the role of vena cava filters, the effects of VTE and its treatment on quality of life, and the impact of anticoagulants on survival.
Published online:
28 October 2008
doi:10.1038/ncponc1244 |
Full Text | PDF (380K)
Angiosarcoma of the breast following surgery and radiotherapy for breast cancer
Breast angiosarcoma following surgery and radiotherapy for breast cancer is a rare but important clinical entity. In this Review the authors discuss data collected from over 250 case reports and provide a comprehensive discussion of the incidence, etiology, histopathology, cytogenetics, presentation, diagnosis, prognosis and management of this tumor type.
Published online:
21 October 2008
doi:10.1038/ncponc1242 |
Full Text | PDF (367K)
New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer
Brain metastases are an increasingly prominent problem in the management of women with metastatic breast cancer. Trastuzumab has provided excellent systemic disease control for many patients; however, many women are now living long enough to develop CNS disease. This Review considers the potential for targeted therapy to provide effective management for brain metastases in patients with ErbB2-positive breast cancer, reviewing in particular the data currently available in this setting for lapatinib.
Published online:
21 October 2008
doi:10.1038/ncponc1243 |
Full Text | PDF (347K)
Capecitabine: have we got the dose right?
Capecitabine is commonly substituted for conventional 5-fluorouracil chemotherapy based on evidence of the efficacy equivalence of these two drugs and the lack of an increase in overall toxic effects when capecitabine is used. This Review summarizes why there may not be a universally applicable dose for capecitabine because of interpatient differences in basic physiology, pharmacogenomics and diet. The authors also discuss which of these factors contribute to the inter-regional geographical variation in capecitabine toxicity, and the reasons for modifying the starting dose.
Published online:
21 October 2008
doi:10.1038/ncponc1240 |
Full Text | PDF (334K)
In silico cancer modeling: is it ready for prime time?
In the era of personalized, systems-driven medicine, computational or in silico modeling and the simulation of disease processes is becoming increasingly important for hypothesis generation and data integration in both experiments and clinics alike. The authors of this Review discuss selected studies on modeling malignant brain tumors and the implications for clinical practice, including trial design and outcome prediction.
Published online:
14 October 2008
doi:10.1038/ncponc1237 |
Full Text | PDF (414K)
Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas
Although the precise mechanisms by which histone deacetylase inhibitors exert their antitumor activity is not known, certain tumor types undergo a favorable response and consequently several agents have now entered clinical trials. Khan and La Thangue discuss recent developments in our understanding of the molecular events that underlie the anticancer effects of histone deacetylase inhibitors and relate this information to the emerging clinical picture for cutaneous T-cell lymphoma and related malignancies.
Published online:
07 October 2008
doi:10.1038/ncponc1238 |
Full Text | PDF (513K)
Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck
Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck have a poor prognosis. Cetuximab represents a clinically relevant advance in the treatment of recurrent and metastatic disease. This rationale for cetuximab as monotherapy and its use in combination with platinum-based chemotherapy for recurrent and/or metastatic disease in the first-line setting is discussed.
Published online:
30 September 2008
doi:10.1038/ncponc1228 |
Full Text | PDF (363K)
Precancerous lesions of the breast
Precancerous lesions of the breast have become a considerable clinical problem. It is not always possible to identify which of these lesions will progress to invasive carcinoma, and tailoring the treatment according to each individual case remains a challenge. This Review describes the genetic alterations in these types of lesions, the importance of histological examination for diagnosis, and the most appropriate surgical and radiotherapy management options.
Published online:
30 September 2008
doi:10.1038/ncponc1239 |
Full Text | PDF (241K)
Case Studies
Noninvasive detection of therapeutic cytolytic T cells with 18F–FHBG PET in a patient with glioma
The authors present the case of a 57-year-old male who was diagnosed with grade IV glioblastoma multiforme and enrolled in a clinical trial of adoptive cellular immunotherapy. The authors used PET imaging technology to image the T cells non-invasively and report the first case using a non-invasive imaging reporter gene/probe technology.
Published online:
18 November 2008
doi:10.1038/ncponc1278 |
Full Text | PDF (576K)
Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib
Anal mucosal melanoma is a disorder with limited treatment options and is associated with a poor prognosis. The authors describe the case of a 79-year-old man who was diagnosed with stage IV anal mucosal melanoma expressing the KIT Val560Asp mutation, and was treated with surgery, radiotherapy, and a combination of sorafenib and temozolomide therapy. The authors discuss the potential therapeutic use of sorafenib in anal mucosal melanoma patients with specific mutations such as the KIT Val560Asp mutation.
Published online:
21 October 2008
doi:10.1038/ncponc1251 |
Full Text | PDF (389K)
Top of page
Until print versions of AOP papers are published, they should be cited in the style "Authorname A et al. (year) Title of article. Nat Clin Pract Oncol, advance online publication, day month year [doi:10.1038/ncponcxxxx]". Once the print version (identical to the AOP) is published, it should be cited as follows: "Authorname A et al. (year) Title of article. Nat Clin Pract Oncol Vol: xxx–xxx, advance online publication, [doi:10.1038/ncponcxxxx]".
